To include your compound in the COVID-19 Resource Center, submit it here.

Clementia takeout to bolster Ipsen’s orphan pipeline

Ipsen Group (Euronext:IPN; Pink:IPSEY) will broaden its rare disease pipeline by acquiring Clementia Pharmaceuticals Inc. (NASDAQ:CMTA) for $1 billion up front.

At $25 per share, the deal price is a 67% premium to Clementia's close of $14.94 Friday, before the deal was announced. Ipsen’s offer includes a $6 per share contingent value right (CVR) tied to Clementia lead compound palovarotene (R667) that is worth

Read the full 634 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers